Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients

Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients

Abstract Background Programmed death ligand‐1 (PD‐L1) expression is a well‐known predictive biomarker of response to immune checkpoint blockade in non‐small cell lung cancer (NSCLC). However, there is limited evidence of the relationship between PD‐L1 expression, clinicopathological features, and th...

Full description

Bibliographic Details
Main Authors: Gonzalo Ruiz, Diego Enrico, Yamil D. Mahmoud, Alan Ruiz, María Florencia Cantarella, Laura Leguina, Mariana Barberis, Asunción Beña, Esteban Brest, Solange Starapoli, Andrea Mendoza Bertelli, Florencia Tsou, Carmen Pupareli, María Pía Coppola, Alejandra Scocimarro, Susana Sena, Patricio Levit, Aldo Perfetti, Enrique Aman, María Romina Girotti, Oscar Arrieta, Claudio Martín, Rubén Salanova
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Thoracic Cancer
Subjects:
programmed death‐ligand 1 (PD‐L1)
non‐small cell lung cancer (NSCLC)
immunohistochemistry (IHC)
driver mutations
genomic alterations
Online Access:https://doi.org/10.1111/1759-7714.15244

Internet

https://doi.org/10.1111/1759-7714.15244

Similar Items